Not only do stent giants Boston Scientific and Johnson & Johnson have to contend with weak sales of drug-coated stents, they also have to worry about next-generation stents from Medtronic and Abbott Labs.
We were reminded of the tough market for stents again this morning, when we read that Boston Scientific stents were apparently frozen out from the Cleveland Clinic, which is among the nation’s most prestigious cardiology centers. Dow Jones Newswires has the story.
J&J, Medtronic and Abbott all said they’ll be selling stents to the Cleveland Clinic, which wants its doctors to sample a range of devices–other than Boston Scientific’s. After the test period, the Clinic expects to narrow the field to one or two products, an official told Dow Jones.
Boston Scientific, which in 2006 inked an 18-month deal to be the clinic’s preferred vendor, wouldn’t comment.
The Medtronic and Abbott stents were both approved earlier this year. Boston Scientific is working to get a next-generation version of its Taxus stent approved for sale in the U.S., Dow Jones notes.
Image from Abbott
Tidak ada komentar:
Posting Komentar